Wilson Liao, MD
Dermatology · San Francisco, CANPI 1528194255
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,450 of the $2,666 with a category attached, or 91.9%. AbbVie accounts for 91.9% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $2,450, more than ten times the $75 reported in 2019.
Across 3 payments — averaging $888.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boehringer Ingelheim$142
- Sun Pharmaceutical Industries Inc.$75
Across 40 payments — averaging $89,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.8M
- LEO Pharma AS$1.1M
- Janssen Research & Development, LLC$377K
- Takeda Pharmaceuticals U.S.A., Inc.$168K
- Novartis$133K
- AbbVie$4K
What the payments were for
- Consulting fees$2,45092%
- Food & beverage$2168%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $2,450 |
| Boehringer Ingelheim | 1 | $142 |
| Sun Pharmaceutical Industries Inc. | 1 | $75 |
How this compares
$2,666 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 40 | $810,008 |
| TremfyaGuselkumab | 39 | $507,635 |
| Taltz AutoinjectorIxekizumab | 36 | $331,400 |
| StelaraUstekinumab | 11 | $217,409 |
| OtezlaApremilast | 36 | $205,126 |
| EnbrelEtanercept | 12 | $164,914 |
| Cosentyx Unoready PenSecukinumab | 16 | $139,044 |
| Taltz SyringeIxekizumab | 15 | $102,072 |
| Dupixent SyringeDupilumab | 27 | $98,905 |
| SotyktuDeucravacitinib | 12 | $82,161 |
| OpzeluraRuxolitinib Phosphate | 18 | $34,717 |
| EucrisaCrisaborole | 12 | $12,453 |
| Acitretin | 25 | $10,098 |
| ZoryveRoflumilast | 11 | $9,121 |
| Clobetasol Propionate | 86 | $6,241 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Francisco
- Tina BhutaniSan Francisco$1.1M
- Sarina ElmariahSan Francisco$510K
- Timothy BergerSan Francisco$270K
- Marlys FassettSan Francisco$168K
- Caren CampbellSan Francisco$149K
- Kathleen WelshSan Francisco$149K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.